Comparing the Efficacy of WeChat-based Patient Education and Conventional Patient Education in the Management of Helicobacter Pylori Eradication
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu hosipital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients aged between 18 and 75 years old and have not been treated before.
Exclusion Criteria:
- Patients who had H. pylori therapy history, using other therapeutic regimens or unwilling to take prescribed medications were excluded. Demographic data, treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control group
|
patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists.
Relevant knowledge of H. pylori eradication was released in the group chat irregularly.
Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
|
|
WeChat group
|
patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists.
Relevant knowledge of H. pylori eradication was released in the group chat irregularly.
Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
eradication rate
Time Frame: 2 months
|
Six weeks after completion of treatment,numbers of patients get H.pylori eradicated supported by negative 13C-UBT results will be investigated by an independent researcher.Then eradication rate in each group will be calculated by using intention-to-treat analysis and per-protocol analysis.
|
2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
compliance
Time Frame: 14 days
|
compliance was evaluated by assessing the total pills patients have taken.Compliance was defined as good when more than 80% or less than 120% of the total pills were taken.
|
14 days
|
|
prevalence of adverse events
Time Frame: 14 days
|
At the follow-up, adverse events complained by patients will be recorded by an independent researcher,meanwhile a 8 point visual analog scale (VAS) was used to evaluate severity of adverse events.
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2021SDU-QILU-111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.